CN109771668A - The purposes of KDM6A gene or KDM6AmRNA - Google Patents
The purposes of KDM6A gene or KDM6AmRNA Download PDFInfo
- Publication number
- CN109771668A CN109771668A CN201910109056.3A CN201910109056A CN109771668A CN 109771668 A CN109771668 A CN 109771668A CN 201910109056 A CN201910109056 A CN 201910109056A CN 109771668 A CN109771668 A CN 109771668A
- Authority
- CN
- China
- Prior art keywords
- drug
- kdm6amrna
- kdm6a
- bladder cancer
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The purposes for treating the drug of bladder cancer is used to prepare the invention discloses KDM6A gene or KDM6AmRNA, the KDM6A gene or KDM6AmRNA can effectively inhibit the transfer of bladder cancer.
Description
Technical field
The present invention relates to the purposes of KDM6A gene or KDM6AmRNA, are especially used to prepare inhibition metastasis of bladder carcinoma
Drug purposes.
Background technique
Bladder cancer is one of most common malignant tumour of urinary system.Cancer in China data show, the death rate of bladder cancer
Increase year by year with disease incidence.Due to lacking effective detection means, bladder cancer patients discovery is mostly advanced stage, advanced bladder carcinoma patient
Mostly with lymphatic metastasis, Lung metastases, hepatic metastases etc..
KDM6A gene is the gene for expressing lysine specificity demethylase 6A (a kind of histone demethylase).
KDM6A is played an important role in differentiation, development and the generation of tumor tissues, development process of individual.KDM6A clpp gene
It plays a significant role except experimental study discloses KDM6A in the generation and cardiovascular growth course of hemopoietic system.KDM6A by
In its demethylation function, also it is reported and plays a role in kinds of tumors as tumor suppressor gene, such as Huppert's disease, esophagus
Cancer and kidney.In addition, the afunction body of KDM6A specific site can lead to the generation of genetic disease Kabuki syndrome.
TCGA database displaying, KDM6A gene have mutation in a plurality of types of cancers, and mutation rate is 20-29% in bladder cancer,
In the 5th.
However, currently without the report about KDM6A gene in terms for the treatment of bladder cancer, especially inhibition bladder metastasis of cancer
Road.
Summary of the invention
The drug for inhibiting bladder metastasis of cancer is used to prepare the purpose of the present invention is to provide KDM6A gene or KDM6AmRNA
Purposes.
The purpose of the present invention is what is be achieved through the following technical solutions.
The present invention provides KDM6A gene or KDM6AmRNA is used to prepare the purposes for treating the drug of bladder cancer, KDM6A base
The sequence of cause is as shown in SEQ ID No.1.
In the present invention, it is preferable that the drug of the treatment bladder cancer is the drug for inhibiting bladder metastasis of cancer.
In the present invention, it is preferable that described that bladder metastasis of cancer is inhibited to refer to that inhibition bladder cancer turns to lymph node, lung or liver
It moves.
In the present invention, it is preferable that the drug includes and carrier-bound KDM6A gene or KDM6AmRNA and pharmacy
Upper acceptable auxiliary material.
In the present invention, it is preferable that in the drug, the KDM6A gene or KDM6AmRNA form lipid in conjunction with carrier
Body.
In the present invention, it is preferable that the liposome is nano liposomes.
In the present invention, it is preferable that the drug include with carrier-bound KDM6AmRNA, and the KDM6AmRNA and carry
Body combines and forms nano liposomes.
In the present invention, it is preferable that the drug is pharmaceutical preparation, and the pharmaceutical preparation is injection.
In the present invention, it is preferable that in the drug, KDM6A gene or KDM6AmRNA are as unique pharmacy activity component.
In the present invention, it is preferable that the drug also includes to treat the chemotherapeutics of bladder cancer as pharmacy activity component.
KDM6A gene of the invention or KDM6AmRNA are used to prepare treatment bladder cancer, especially inhibition bladder metastasis of cancer
The purposes of drug.
Detailed description of the invention
Fig. 1 is the relationship between bladder cancer patients survival rate and KDM6A expression.
Fig. 2 is the Westwen-Blot testing result figure of RT-4 and KU19-19 bladder cancer cell.
Fig. 3 is the scratch experiment result figure of RT-4 and KU19-19 bladder cancer cell.
Fig. 4 is the Transwell experimental result picture of RT-4 and KU19-19 bladder cancer cell.
Specific embodiment
The present invention is further illustrated combined with specific embodiments below, but protection scope of the present invention is not limited to
This.
In the present invention, the nucleotide sequence of KDM6A gene be it is known, as shown in SEQ ID No.1.
The present invention provides KDM6A gene or KDM6AmRNA is used to prepare the purposes for treating the drug of bladder cancer.The present invention
In, the treatment bladder cancer includes inhibiting the transfer of bladder cancer；Especially inhibit bladder cancer to lymph node, lung or the transfer of liver.
According to embodiment of the present invention, the treatment bladder cancer refers to the transfer for inhibiting bladder cancer；Especially inhibit bladder cancer
To lymph node, lung or the transfer of liver.
On the one hand, the KDM6A gene or KDM6AmRNA are used to prepare the purposes of the drug for the treatment of bladder cancer, can be
It is applied to preparation treatment using the KDM6A gene as the action target for the treatment of bladder cancer (especially inhibition bladder metastasis of cancer)
The drug of bladder cancer.Action target of the KDM6A gene as treatment bladder cancer refers to that drug is made for the enhancing of KDM6A gene
With.
On the other hand, the KDM6A gene or KDM6AmRNA are used to prepare the purposes of the drug for the treatment of bladder cancer, may be used also
To be that drug directly is made in KDM6A gene and/or KDM6AmRNA to be used to treat bladder cancer, to increase the table of KDM6A gene
Up to amount.
In the present invention, the drug include with carrier-bound KDM6A gene or KDM6AmRNA, and can pharmaceutically connect
The auxiliary material received.KDM6A gene or KDM6AmRNA can be wrapped by and in conjunction with carrier, such as be covered by shape in carrier
At liposome, especially nano liposomes, so that its activity be made to keep stablizing.The carrier can be conventional in pharmaceutical field
Cladding uses carrier.
According to embodiment of the present invention, the drug include with carrier-bound KDM6AmRNA, and it is described
KDM6AmRNA forms nano liposomes in conjunction with carrier.
In the present invention, the drug is pharmaceutical preparation.The dosage form of the pharmaceutical preparation is unlimited.It is preferred real according to the present invention
Mode is applied, the pharmaceutical preparation is injection.
In the present invention, the drug can using KDM6A gene or KDM6AmRNA as unique pharmacy activity component,
It may include the chemotherapeutics of other treatment bladder cancer.The chemotherapeutics not will lead to the KDM6A gene or KDM6AmRNA
Go bad or loses activity.
Below by way of specific experiment, illustrate effect of the KDM6A to metastasis of bladder carcinoma.
Embodiment 1
1. experimental material and method:
Bladder cancer cell line: RT-4 (KDM6A wild type), KU19-19 (KDM6A deletion form) are purchased from ATCC (American
Type Culture Collection, American Type Culture Collection Center)；Gibco fetal calf serum, Gibco lowlenthal serum,
Gibco TRYPSIN0.25%EDTA: Invitrogen company, the U.S.；PBS, 1640 culture medium, McCoy's5A culture solution: lucky
Promise biological medicine technology Co., Ltd；KDM6A primary antibody: Genetex company, the U.S.；E-cadherin primary antibody, N-cadherin mono-
Anti-, β-catenin primary antibody, Vimentin primary antibody, GAPDH primary antibody: CST company, the U.S..
2, the immunohistochemical assay of clinical sample:
Bladder cancer patients from Zhejiang Provincial People's Hospital, the relationship of statistics patient survival and KDM6A expression.
3, In vitro cell experiment:
1) culture of RT-4, KU19-19 bladder cancer cell
RT-4 cell uses the McCoy's5A culture solution containing 10% fetal calf serum (to include 100U/ml Benzylpenicillin sodium salt and 100U/
Ml streptomysin) culture；KU19-19 cell use containing 10% fetal calf serum 1640 culture medium (include 100U/ml Benzylpenicillin sodium salt and
100U/ml streptomysin) culture, containing 5%CO237 DEG C of constant incubators in cultivate, when cell it is long to about 80% when, with containing
0.25% trypsin digestion of 0.02%EDTA 2 minutes adds the culture solution containing 10% serum to terminate reaction, according to 1 after centrifugation:
3 passages, logarithmic growth phase cell culture is for testing.
2) Westwen-Blot immunoblot experiment
RT-4, KU19-19 cell of logarithmic growth phase extract albumen respectively, and Westwen-Blot detects mesenchyma conversion
Relevant protein expression level.
3) scratch experiment
RT-4, KU19-19 cell of logarithmic growth phase are respectively with 0.25% trypsin digestion 2 containing 0.02%EDTA
Minute, add the culture solution containing 10% serum to terminate reaction, takes 10ul cell to be added to cell after centrifugation plus after the mixing of appropriate culture medium
Number, takes 5 × 10 in tally5A cell is put into six orifice plates, and culture draws " well " in six orifice plate bottoms with yellow pipette tips afterwards for 24 hours,
It is replaced with serum-free medium, observes and takes pictures every 6h, experiment is terminated when cell healing rate is up to 50%.
4) Transwell is tested
The cell Transwell is put into one 24 orifice bores, respectively by 1 × 106A RT-4 cell and KU19-19 cell add
Onto cell inner membrance, 24 orifice plates add the culture medium containing 10% fetal calf serum, culture medium small indoor plus without fetal calf serum, and 37 DEG C
5%CO28~48h is cultivated in incubator, proposes that cell, fixed cell remove inside cell, with violet staining, after cleaning
It takes pictures.
4, experimental result:
Shown by immunohistochemistry: KDM6A high expression in the normal tissue, low expression in invasive bladder cancer prompt
KDM6A low expression may be related (Fig. 1) to the infiltration of bladder cancer and transfer.Westwen-Blot proves that KDM6A missing promotes
The expression (Fig. 2) of metastasis related protein Vimentin, N-cadherin, ZEB；Scratch experiment (Fig. 3) and Transwell experiment
(Fig. 4) confirms that the transfer ability of KDM6A missing bladder cancer cell is significantly stronger than its wild-type cell.
Present invention is not limited to the embodiments described above, without departing from the essence of the present invention, this field skill
Any deformation, improvement, the replacement that art personnel are contemplated that each fall within the scope of the present invention.
Sequence table
<110>Sui Xinbing
<120>purposes of KDM6A gene or KDM6AmRNA
<130> YC12019010002-A
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 10763
<212> DNA
<213>homo sapiens (Homo sapiens)
<400> 1
aacaaaatat taacgcttac aatttccatt cgccattcag gctgcgcaac tgttgggaag 60
ggcgatcggt gcgggcctct tcgctattac gccagctggc gaaaggggga tgtgctgcaa 120
ggcgattaag ttgggtaacg ccagggtttt cccagtcacg acgttgtaaa acgacggcca 180
gtgccaagct gatctataca ttgaatcaat attggcaatt agccatatta gtcattggtt 240
atatagcata aatcaatatt ggctattggc cattgcatac gttgtatcta tatcataata 300
tgtacattta tattggctca tgtccaatat gaccgccatg ttgacattga ttattgacta 360
gttattaata gtaatcaatt acggggtcat tagttcatag cccatatatg gagttccgcg 420
ttacataact tacggtaaat ggcccgcctg gctgaccgcc caacgacccc cgcccattga 480
cgtcaataat gacgtatgtt cccatagtaa cgccaatagg gactttccat tgacgtcaat 540
gggtggagta tttacggtaa actgcccact tggcagtaca tcaagtgtat catatgccaa 600
gtccgccccc tattgacgtc aatgacggta aatggcccgc ctggcattat gcccagtaca 660
tgaccttacg ggactttcct acttggcagt acatctacgt attagtcatc gctattacca 720
tggtgatgcg gttttggcag tacaccaatg ggcgtggata gcggtttgac tcacggggat 780
ttccaagtct ccaccccatt gacgtcaatg ggagtttgtt ttggcaccaa aatcaacggg 840
actttccaaa atgtcgtaat aaccccgccc cgttgacgca aatgggcggt aggcgtgtac 900
ggtgggaggt ctatataagc agagctcgtt tagtgaaccg tcagaatttt gtaatacgac 960
tcactatagg gcggccggga attcgtcgac tggatccggt accgaggaga tctgccgccg 1020
cgatcgccat gaaatcctgc ggagtgtcgc tcgctaccgc cgccgctgcc gccgccgctt 1080
tcggtgatga ggaaaagaaa atggcggcgg gaaaagcgag cggcgagagc gaggaggcgt 1140
cccccagcct gacagccgag gagagggagg cgctcggcgg actggacagc cgcctcttcg 1200
ggttcgtgag atttcatgaa gatggcgcca ggacgaaggc cctactgggc aaggctgttc 1260
gctgctatga atctctaatc ttaaaagctg aaggaaaagt ggagtctgat ttcttttgtc 1320
aattaggtca cttcaacctc ttattggaag attatccaaa agcattatct gcataccaga 1380
ggtactacag tttacagtct gactactgga agaatgctgc ctttttatat ggtcttggtt 1440
tggtctactt ccattataat gcatttcagt gggcaattaa agcatttcag gaggtgcttt 1500
atgttgatcc cagcttttgt cgagccaagg aaattcattt acgacttggg cttatgttca 1560
aagtgaacac agactatgag tctagtttaa agcattttca gttagctttg gttgactgta 1620
atccctgcac tttgtccaat gctgaaattc aatttcacat tgcccactta tatgaaaccc 1680
agaggaaata tcattctgca aaagaagctt atgaacaact tttgcagaca gagaatcttt 1740
ctgcacaagt aaaagcaact gtcttacaac agttaggttg gatgcatcac actgtagatc 1800
tcctgggaga taaagccacc aaggaaagct atgctattca gtatctccaa aagtccttgg 1860
aagcagatcc taattctggc cagtcctggt atttcctcgg aaggtgctat tcaagtattg 1920
ggaaagttca ggatgccttt atatcttaca ggcagtctat tgataaatca gaagcaagtg 1980
cagatacatg gtgttcaata ggtgtgctat atcagcagca aaatcagccc atggatgctt 2040
tacaggccta tatttgtgct gtacaattgg accatggcca tgctgcagcc tggatggacc 2100
taggcactct ctatgaatcc tgcaaccagc ctcaggatgc cattaaatgc tacttaaatg 2160
caactagaag caaaagttgt agtaatacct ctgcacttgc agcacgaatt aagtatttac 2220
aggctcagtt gtgtaacctt ccacaaggta gtctacagaa taaaactaaa ttacttccta 2280
gtattgagga ggcgtggagc ctaccaattc ccgcagagct tacctccagg cagggtgcca 2340
tgaacacagc acagcagaat acttctgaca attggagtgg tggacatgct gtgtcacatc 2400
ctccagtaca gcaacaagct cattcatggt gtttgacacc acagaaatta cagcatttgg 2460
aacagctccg cgcaaataga aataatttaa atccagcaca gaaactgatg ctggaacagc 2520
tggaaagtca gtttgtctta atgcaacaac accaaatgag accaacagga gttgcacagg 2580
tacgatctac tggaattcct aatgggccaa cagctgactc atcactgcct acaaactcag 2640
tctctggcca gcagccacag cttgctctga ccagagtgcc tagcgtctct cagcctggag 2700
tccgtcctgc ctgccctggg cagcctttgg ccaatggacc cttttctgca ggccatgttc 2760
cctgtagcac atcaagaacg ctgggaagta cagacactat tttgataggc aataatcata 2820
taacaggaag tggaagtaat ggaaacgtgc cttacctgca gcgaaacgca ctcactctac 2880
ctcataaccg cacaaacctg accagcagcg cagaggagcc gtggaaaaac caactatcta 2940
actccactca ggggcttcac aaaggtcaga gttcacattc ggcaggtcct aatggtgaac 3000
gacctctctc ttccactggg ccttcccagc atctccaggc agctggctct ggtattcaga 3060
atcagaacgg acatcccacc ctgcctagca attcagtaac acagggggct gctctcaatc 3120
acctctcctc tcacactgct acctcaggtg gacaacaagg cattacctta accaaagaga 3180
gcaagccttc aggaaacata ttgaaggtgc ctgaaacaag caggcacact ggagagacac 3240
ctaacagcac tgccagtgtc gagggacttc ctaatcatgt ccatcagatg acggcagatg 3300
ctgtttgcag tcctagccat ggagattcta agtcaccagg tttactaagt tcagacaatc 3360
ctcagctctc tgccttgttg atgggaaaag ccaataacaa tgtgggtact ggaacctgtg 3420
acaaagtcaa taacatccac ccagctgttc atacaaagac tgataactct gttgcctctt 3480
caccatcttc agccatttca acagcaacac cttctccaaa atccactgag cagacaacca 3540
caaacagtgt taccagcctt aacagccctc acagtgggct acacacaatt aatggagaag 3600
ggatggaaga atctcagagc cccatgaaaa cagatctgct tctggttaac cacaaaccta 3660
gtccacagat cataccatca atgtctgtgt ccatataccc cagctcagca gaagttctga 3720
aggcatgcag gaatctaggt aaaaatggct tatctaacag tagcattttg ttggataaat 3780
gtccacctcc aagaccacca tcttcaccat accctccctt gccaaaggac aagttgaatc 3840
cacctacacc tagtatttac ttggaaaata aacgtgatgc tttctttcct ccattacatc 3900
aattttgtac aaatccgaac aaccctgtta cagtaatacg tggccttgct ggagctctta 3960
agttagacct gggacttttc tctactaaaa ctttggtgga agctaacaat gaacatatgg 4020
tagaagtgag gacacagttg ttgcagccag cagatgaaaa ctgggatccc actggaacaa 4080
agaaaatctg gcattgtgaa agtaatagat ctcatactac aattgctaaa tatgcacagt 4140
accaggcctc ctcattccag gaatcattga gagaagaaaa tgaaaaaaga agtcatcata 4200
aagaccactc agatagtgaa tctacatcgt cagataattc tgggaggagg aggaaaggac 4260
cctttaaaac cataaagttt gggaccaata ttgacctatc tgatgacaaa aagtggaagt 4320
tgcagctaca tgagctgact aaacttcctg cttttgtgcg tgtcgtatca gcaggaaatc 4380
ttctaagcca tgttggtcat accatattgg gcatgaacac agttcaacta tacatgaaag 4440
ttccagggag cagaacacca ggtcatcagg aaaataacaa cttctgttca gttaacataa 4500
atattggccc aggtgactgt gaatggtttg ttgttcctga aggttactgg ggtgttctga 4560
atgacttctg tgaaaaaaat aatttgaatt tcctaatggg ttcttggtgg cccaatcttg 4620
aagatcttta tgaagcaaat gttccagtgt ataggtttat tcagcgacct ggagatttgg 4680
tctggataaa tgcaggcact gttcattggg ttcaggctat tggctggtgc aacaacattg 4740
cttggaatgt tggtccactt acagcctgcc agtataaatt ggcagtggaa cggtacgaat 4800
ggaacaaatt gcaaagtgtg aagtcaatag tacccatggt tcatctttcc tggaatatgg 4860
cacgaaatat caaggtctca gatccaaagc tttttgaaat gattaagtat tgtcttctaa 4920
gaactctgaa gcaatgtcag acattgaggg aagctctcat tgctgcagga aaagagatta 4980
tatggcatgg gcggacaaaa gaagaaccag ctcattactg tagcatttgt gaagtggagg 5040
tttttgatct gctttttgtc actaatgaga gtaattcacg aaagacctac atagtacatt 5100
gccaagattg tgcacgaaaa acaagcggaa acttggaaaa ctttgtggtg ctagaacagt 5160
acaaaatgga ggacctgatg caagtctatg accaatttac attagctcct ccattaccat 5220
ccgcctcatc tacgcgtacg cggccgctcg agatggagag cgacgagagc ggcctgcccg 5280
ccatggagat cgagtgccgc atcaccggca ccctgaacgg cgtggagttc gagctggtgg 5340
gcggcggaga gggcaccccc gagcagggcc gcatgaccaa caagatgaag agcaccaaag 5400
gcgccctgac cttcagcccc tacctgctga gccacgtgat gggctacggc ttctaccact 5460
tcggcaccta ccccagcggc tacgagaacc ccttcctgca cgccatcaac aacggcggct 5520
acaccaacac ccgcatcgag aagtacgagg acggcggcgt gctgcacgtg agcttcagct 5580
accgctacga ggccggccgc gtgatcggcg acttcaaggt gatgggcacc ggcttccccg 5640
aggacagcgt gatcttcacc gacaagatca tccgcagcaa cgccaccgtg gagcacctgc 5700
accccatggg cgataacgat ctggatggca gcttcacccg caccttcagc ctgcgcgacg 5760
gcggctacta cagctccgtg gtggacagcc acatgcactt caagagcgcc atccacccca 5820
gcatcctgca gaacgggggc cccatgttcg ccttccgccg cgtggaggag gatcacagca 5880
acaccgagct gggcatcgtg gagtaccagc acgccttcaa gaccccggat gcagatgccg 5940
gtgaagaaag agtttaaacg gccggccgcg gtcatagctg tttcctgaac agatcccggg 6000
tggcatccct gtgacccctc cccagtgcct ctcctggccc tggaagttgc cactccagtg 6060
cccaccagcc ttgtcctaat aaaattaagt tgcatcattt tgtctgacta ggtgtccttc 6120
tataatatta tggggtggag gggggtggta tggagcaagg ggcaagttgg gaagacaacc 6180
tgtagggcct gcggggtcta ttgggaacca agctggagtg cagtggcaca atcttggctc 6240
actgcaatct ccgcctcctg ggttcaagcg attctcctgc ctcagcctcc cgagttgttg 6300
ggattccagg catgcatgac caggctcagc taatttttgt ttttttggta gagacggggt 6360
ttcaccatat tggccaggct ggtctccaac tcctaatctc aggtgatcta cccaccttgg 6420
cctcccaaat tgctgggatt acaggcgtga accactgctc ccttccctgt ccttctgatt 6480
ttaaaataac tataccagca ggaggacgtc cagacacagc ataggctacc tggccatgcc 6540
caaccggtgg gacatttgag ttgcttgctt ggcactgtcc tctcatgcgt tgggtccact 6600
cagtagatgc ctgttgaatt gggtacgcgg ccagcttggc tgtggaatgt gtgtcagtta 6660
gggtgtggaa agtccccagg ctccccagca ggcagaagta tgcaaagcat gcatctcaat 6720
tagtcagcaa ccaggtgtgg aaagtcccca ggctccccag caggcagaag tatgcaaagc 6780
atgcatctca attagtcagc aaccatagtc ccgcccctaa ctccgcccat cccgccccta 6840
actccgccca gttccgccca ttctccgccc catggctgac taattttttt tatttatgca 6900
gaggccgagg ccgcctcggc ctctgagcta ttccagaagt agtgaggagg cttttttgga 6960
ggcctaggct tttgcaaaaa gctcccggga gcttgtatat ccattttcgg atctgatcaa 7020
gagacaggat gaggatcgtt tcgcatgatt gaacaagatg gattgcacgc aggttctccg 7080
gccgcttggg tggagaggct attcggctat gactgggcac aacagacaat cggctgctct 7140
gatgccgccg tgttccggct gtcagcgcag gggcgcccgg ttctttttgt caagaccgac 7200
ctgtccggtg ccctgaatga actgcaggac gaggcagcgc ggctatcgtg gctggccacg 7260
acgggcgttc cttgcgcagc tgtgctcgac gttgtcactg aagcgggaag ggactggctg 7320
ctattgggcg aagtgccggg gcaggatctc ctgtcatctc accttgctcc tgccgagaaa 7380
gtatccatca tggctgatgc aatgcggcgg ctgcatacgc ttgatccggc tacctgccca 7440
ttcgaccacc aagcgaaaca tcgcatcgag cgagcacgta ctcggatgga agccggtctt 7500
gtcgatcagg atgatctgga cgaagagcat caggggctcg cgccagccga actgttcgcc 7560
aggctcaagg cgcgcatgcc cgacggcgag gatctcgtcg tgacccatgg cgatgcctgc 7620
ttgccgaata tcatggtgga aaatggccgc ttttctggat tcatcgactg tggccggctg 7680
ggtgtggccg accgctatca ggacatagcg ttggctaccc gtgatattgc tgaagagctt 7740
ggcggcgaat gggctgaccg cttcctcgtg ctttacggta tcgccgctcc cgattcgcag 7800
cgcatcgcct tctatcgcct tcttgacgag ttcttctgag cgggactctg gggttcgaaa 7860
tgaccgacca agcgacgccc aacctgccat cacgagattt cgattccacc gccgccttct 7920
atgaaaggtt gggcttcgga atcgttttcc gggacgccgg ctggatgatc ctccagcgcg 7980
gggatctcat gctggagttc ttcgcccacc ccaacttgtt tattgcagct tataatggtt 8040
acaaataaag caatagcatc acaaatttca caaataaagc atttttttca ctgcattcta 8100
gttgtggttt gtccaaactc atcaatgtat cttatcatgt ctgtataccg tcgacctcta 8160
gctagagctt ggcgtaatca tggtcatagc tgtttcctgt gtgaaattgt tatccgctca 8220
caattccaca caacatacga gccggaagca taaagtgtaa agcctggggt gcctaatgag 8280
tgagctaact cacattaatt gcgttgcgct cactgcccgc tttccagtcg ggaaacctgt 8340
cgtgccagct gcattaatga atcggccaac gcgcggggag aggcggtttg cgtattgggc 8400
gctcttccgc ttcctcgctc actgactcgc tgcgctcggt cgttcggctg cggcgagcgg 8460
tatcagctca ctcaaaggcg gtaatacggt tatccacaga atcaggggat aacgcaggaa 8520
agaacatgtg agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg 8580
cgtttttcca taggctccgc ccccctgacg agcatcacaa aaatcgacgc tcaagtcaga 8640
ggtggcgaaa cccgacagga ctataaagat accaggcgtt tccccctgga agctccctcg 8700
tgcgctctcc tgttccgacc ctgccgctta ccggatacct gtccgccttt ctcccttcgg 8760
gaagcgtggc gctttctcat agctcacgct gtaggtatct cagttcggtg taggtcgttc 8820
gctccaagct gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg 8880
gtaactatcg tcttgagtcc aacccggtaa gacacgactt atcgccactg gcagcagcca 8940
ctggtaacag gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtggt 9000
ggcctaacta cggctacact agaagaacag tatttggtat ctgcgctctg ctgaagccag 9060
ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa acaaaccacc gctggtagcg 9120
gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt 9180
tgatcttttc tacggggtct gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg 9240
tcatgagatt atcaaaaagg atcttcacct agatcctttt aaattaaaaa tgaagtttta 9300
aatcaatcta aagtatatat gagtaaactt ggtctgacag ttaccaatgc ttaatcagtg 9360
aggcacctat ctcagcgatc tgtctatttc gttcatccat agttgcctga ctccccgtcg 9420
tgtagataac tacgatacgg gagggcttac catctggccc cagtgctgca atgataccgc 9480
gagacccacg ctcaccggct ccagatttat cagcaataaa ccagccagcc ggaagggccg 9540
agcgcagaag tggtcctgca actttatccg cctccatcca gtctattaat tgttgccggg 9600
aagctagagt aagtagttcg ccagttaata gtttgcgcaa cgttgttgcc attgctacag 9660
gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt cagctccggt tcccaacgat 9720
caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc ggttagctcc ttcggtcctc 9780
cgatcgttgt cagaagtaag ttggccgcag tgttatcact catggttatg gcagcactgc 9840
ataattctct tactgtcatg ccatccgtaa gatgcttttc tgtgactggt gagtactcaa 9900
ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg ctcttgcccg gcgtcaatac 9960
gggataatac cgcgccacat agcagaactt taaaagtgct catcattgga aaacgttctt 10020
cggggcgaaa actctcaagg atcttaccgc tgttgagatc cagttcgatg taacccactc 10080
gtgcacccaa ctgatcttca gcatctttta ctttcaccag cgtttctggg tgagcaaaaa 10140
caggaaggca aaatgccgca aaaaagggaa taagggcgac acggaaatgt tgaatactca 10200
tactcttcct ttttcaatat tattgaagca tttatcaggg ttattgtctc atgagcggat 10260
acatatttga atgtatttag aaaaataaac aaataggggt tccgcgcaca tttccccgaa 10320
aagtgccacc tgacgcgccc tgtagcggcg cattaagcgc ggcgggtgtg gtggttacgc 10380
gcagcgtgac cgctacactt gccagcgccc tagcgcccgc tcctttcgct ttcttccctt 10440
cctttctcgc cacgttcgcc ggctttcccc gtcaagctct aaatcggggg ctccctttag 10500
ggttccgatt tagtgcttta cggcacctcg accccaaaaa acttgattag ggtgatggtt 10560
cacgtagtgg gccatcgccc tgatagacgg tttttcgccc tttgacgttg gagtccacgt 10620
tctttaatag tggactcttg ttccaaactg gaacaacact caaccctatc tcggtctatt 10680
cttttgattt ataagggatt ttgccgattt cggcctattg gttaaaaaat gagctgattt 10740
aacaaaaatt taacgcgaat ttt 10763
Claims (10)
1.KDM6A gene or KDM6AmRNA are used to prepare the purposes of the drug for the treatment of bladder cancer, which is characterized in that the KDM6A
The sequence of gene is as shown in SEQ ID No.1.
2. purposes according to claim 1, which is characterized in that the drug of the treatment bladder cancer is to inhibit bladder metastasis of cancer
Drug.
3. purposes according to claim 2, which is characterized in that the inhibition bladder metastasis of cancer, which refers to, inhibits bladder cancer to leaching
It fawns on, the transfer of lung or liver.
4. purposes according to claim 3, which is characterized in that the drug include with carrier-bound KDM6A gene or
KDM6AmRNA and pharmaceutically acceptable auxiliary material.
5. purposes according to claim 4, which is characterized in that in the drug, the KDM6A gene or KDM6AmRNA
Liposome is formed in conjunction with carrier.
6. purposes according to claim 5, which is characterized in that the liposome is nano liposomes.
7. purposes according to claim 1, which is characterized in that the drug include with carrier-bound KDM6AmRNA, and
The KDM6AmRNA forms nano liposomes in conjunction with carrier.
8. purposes according to claim 1-7, which is characterized in that the drug is pharmaceutical preparation, and the medicine
Object preparation is injection.
9. purposes according to claim 1-6, which is characterized in that in the drug, KDM6A gene or
KDM6AmRNA is as unique pharmacy activity component.
10. purposes according to claim 1-7, which is characterized in that the drug also includes treatment bladder cancer
Chemotherapeutics is as pharmacy activity component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910109056.3A CN109771668A (en) | 2019-02-03 | 2019-02-03 | The purposes of KDM6A gene or KDM6AmRNA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910109056.3A CN109771668A (en) | 2019-02-03 | 2019-02-03 | The purposes of KDM6A gene or KDM6AmRNA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109771668A true CN109771668A (en) | 2019-05-21 |
Family
ID=66503189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910109056.3A Pending CN109771668A (en) | 2019-02-03 | 2019-02-03 | The purposes of KDM6A gene or KDM6AmRNA |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109771668A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012090073A2 (en) * | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| CN106755547A (en) * | 2017-03-15 | 2017-05-31 | 上海亿康医学检验所有限公司 | The Non-invasive detection and its recurrence monitoring method of a kind of carcinoma of urinary bladder |
| CN107096015A (en) * | 2017-03-01 | 2017-08-29 | 中国人民解放军第二军医大学 | The antivirus action of novel antiviral molecule Kdm6a a kind of and its application |
-
2019
- 2019-02-03 CN CN201910109056.3A patent/CN109771668A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012090073A2 (en) * | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| CN107096015A (en) * | 2017-03-01 | 2017-08-29 | 中国人民解放军第二军医大学 | The antivirus action of novel antiviral molecule Kdm6a a kind of and its application |
| CN106755547A (en) * | 2017-03-15 | 2017-05-31 | 上海亿康医学检验所有限公司 | The Non-invasive detection and its recurrence monitoring method of a kind of carcinoma of urinary bladder |
Non-Patent Citations (5)
| Title |
|---|
| GARRETT M.DANCIK: "A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors", 《STEM CELLS》 * |
| MEEKS JJ: "Molecular Landscape of Non-Muscle Invasive Bladder Cancer", 《CANCER CELL》 * |
| MICHAEL L.NICKERSON: "Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.", 《CLIN CANCER RES》 * |
| 赵广荣: "《现代生命科学与生物技术》", 31 October 2008, 天津大学出版社 * |
| 陈敏章: "《中华内科学》", 31 October 1999, 人民卫生出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108410877A (en) | The sgRNA of CRISPR-Cas9 targeting knock outs people's cell SANIL1 genes and its specificity | |
| US9163219B2 (en) | Single expression vector for generation of a virus with a segmented genome | |
| KR101320489B1 (en) | Serum-free stable transfection and production of recombinant human proteins in human cell lines | |
| AU2019343251A1 (en) | Novel interleukin 2 and use thereof | |
| US6692966B2 (en) | Packaging systems for human recombinant adenovirus to be used in gene therapy | |
| CN101208435A (en) | Improved expression elements | |
| US20030180740A1 (en) | Differential expression screening method | |
| CN109771668A (en) | The purposes of KDM6A gene or KDM6AmRNA | |
| CN111471785A (en) | Candida albicans detection kit based on RPA rapid detection technology | |
| CN110540962B (en) | Method for preparing human definitive endoderm cells | |
| CN114908119A (en) | Method for improving expression quantity of recombinant protein | |
| CN114908120A (en) | Method for improving expression quantity of recombinant protein | |
| CN109529051A (en) | Saliva acyltransferase recombinant plasmid and its with pemetrexed preparation inhibit bladder cancer proliferation and invasion drug in application | |
| CN106520831B (en) | Method for modifying mammalian genome | |
| CN114591417B (en) | Human single chain insulin analogues and uses thereof | |
| US20040248081A1 (en) | LANA viral protein binding sites | |
| CN105002213A (en) | Unconformable deletable novel non-viral vector, and construction method and use thereof | |
| CN110846311A (en) | Preparation of PTC stable cell line by using inhibitory tRNA system and application thereof | |
| CN113846124A (en) | Nucleic acid construct for gene therapy of diseases related to glycometabolism | |
| CN114908110A (en) | Method for improving expression quantity of recombinant protein | |
| CN113584065A (en) | Multi-method combined large-fragment DNA recombination method | |
| US20040266715A1 (en) | Neurite regeneration | |
| KR101578445B1 (en) | Recombinant foot-and-mouth disease virus expressing P1-protective antigen of middle-east-derived Asia type and the manufacturing method | |
| CN114645066B (en) | Nucleic acid construct for gene therapy of AIDS | |
| KR20090106474A (en) | Genetic ablation of the PRP gene cells using a targeted promoter trap strategy for production of serum-free recombinant proteins as therapeuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190521 |